Questions over safety and effectiveness of new Alzheimer’s drug
Investigation raises concerns about excess deaths, missing safety data, questionable effectiveness, and financial ties among expert advisors 7 of the 8 doctors on review panel received direct payments from drug companies The safety and effectiveness of donanemab - an Alzheimer’s drug recently approved by the US Food & Drug Administration ...